A proposal for staging COVID‐19 coagulopathy

Coronavirus disease 2019 (COVID‐19) is associated with significant hypercoagulability. However, despite prophylactic anticoagulation, critically ill patients with this condition develop thromboses. This forum discusses the lungs as the epicenter for the hemostatic issues, puts forward a proposal for...

Descripción completa

Detalles Bibliográficos
Autores principales: Thachil, Jecko, Cushman, Mary, Srivastava, Alok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Forum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272892/
https://www.ncbi.nlm.nih.gov/pubmed/32685880
http://dx.doi.org/10.1002/rth2.12372
_version_ 1783542323730186240
author Thachil, Jecko
Cushman, Mary
Srivastava, Alok
author_facet Thachil, Jecko
Cushman, Mary
Srivastava, Alok
author_sort Thachil, Jecko
collection PubMed
description Coronavirus disease 2019 (COVID‐19) is associated with significant hypercoagulability. However, despite prophylactic anticoagulation, critically ill patients with this condition develop thromboses. This forum discusses the lungs as the epicenter for the hemostatic issues, puts forward a proposal for staging COVID‐19 coagulopathy based on available diagnostic markers, and suggest considering current and future treatment options based on these different stages.
format Online
Article
Text
id pubmed-7272892
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72728922020-06-05 A proposal for staging COVID‐19 coagulopathy Thachil, Jecko Cushman, Mary Srivastava, Alok Res Pract Thromb Haemost Forum Coronavirus disease 2019 (COVID‐19) is associated with significant hypercoagulability. However, despite prophylactic anticoagulation, critically ill patients with this condition develop thromboses. This forum discusses the lungs as the epicenter for the hemostatic issues, puts forward a proposal for staging COVID‐19 coagulopathy based on available diagnostic markers, and suggest considering current and future treatment options based on these different stages. John Wiley and Sons Inc. 2020-07-06 /pmc/articles/PMC7272892/ /pubmed/32685880 http://dx.doi.org/10.1002/rth2.12372 Text en © 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Forum
Thachil, Jecko
Cushman, Mary
Srivastava, Alok
A proposal for staging COVID‐19 coagulopathy
title A proposal for staging COVID‐19 coagulopathy
title_full A proposal for staging COVID‐19 coagulopathy
title_fullStr A proposal for staging COVID‐19 coagulopathy
title_full_unstemmed A proposal for staging COVID‐19 coagulopathy
title_short A proposal for staging COVID‐19 coagulopathy
title_sort proposal for staging covid‐19 coagulopathy
topic Forum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272892/
https://www.ncbi.nlm.nih.gov/pubmed/32685880
http://dx.doi.org/10.1002/rth2.12372
work_keys_str_mv AT thachiljecko aproposalforstagingcovid19coagulopathy
AT cushmanmary aproposalforstagingcovid19coagulopathy
AT srivastavaalok aproposalforstagingcovid19coagulopathy
AT thachiljecko proposalforstagingcovid19coagulopathy
AT cushmanmary proposalforstagingcovid19coagulopathy
AT srivastavaalok proposalforstagingcovid19coagulopathy

Ejemplares similares